We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Understanding the Adverse Effects of Ocriplasmin

David C. Beebe, PhD1
[+] Author Affiliations
1Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, Missouri
JAMA Ophthalmol. 2015;133(2):229. doi:10.1001/jamaophthalmol.2014.4484.
Text Size: A A A
Published online


To the Editor Recent reports of loss of vision after injection of ocriplasmin for vitreomacular traction cite the substrates of this enzyme as fibronectin and laminin.13 Not surprisingly, these are the same substrates mentioned in the package insert for this enzyme and are its “intended” targets at the vitreoretinal interface.4 Speculation about the adverse effects of the enzyme focused exclusively on these substrates. The reason for vision loss appears to involve damage to the photoreceptor outer and inner segments, suggesting that ocriplasmin may have broader substrate specificity.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





February 1, 2015
Michael D. Tibbetts, MD; Elias Reichel, MD; Andre J. Witkin, MD
1Department of Ophthalmology, Tufts Medical Center, Boston, Massachusetts
2New England Eye Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts
JAMA Ophthalmol. 2015;133(2):229-230. doi:10.1001/jamaophthalmol.2014.4503.
February 1, 2015
Mark W. Johnson, MD; Abigail T. Fahim, MD, PhD
1Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan Medical School, Ann Arbor
JAMA Ophthalmol. 2015;133(2):230. doi:10.1001/jamaophthalmol.2014.4505.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...